Treace Medical Concepts Reports Tomorrow With Revenue Mix Still Dragging

Treace Medical Concepts (NASDAQ: TMCI) is scheduled to report second quarter 2026 earnings before the market opens on Friday, August 7, 2026. The medical technology company, which specializes in surgical treatment of bunions and midfoot deformities, faces investor scrutiny as analysts expect another quarterly loss amid ongoing profitability challenges. With the stock showing strong technical momentum but persistent bottom-line pressure, the report will test whether operational improvements can offset year-over-year earnings deterioration.

Part 1: Earnings Preview

Treace Medical Concepts is a medical technology company focused on driving innovation in the surgical treatment of bunions and related midfoot deformities through its proprietary Lapiplasty® 3D Bunion Correction® System and Adductoplasty® Midfoot Correction System. The company serves an addressable market of over 1 million annual surgical candidates in the United States.

For the second quarter of 2026, analysts expect Treace to report a loss of $-0.30 per share on revenue of approximately $43.91 million. The company most recently reported first quarter 2026 earnings of $-0.28 per share, which beat estimates of $-0.31. Compared to the same quarter last year when Treace posted a loss of $-0.28 per share, the current estimate represents a 7.14% deterioration in year-over-year earnings performance.

Three key themes define this earnings story:

Revenue trajectory and market penetration: With quarterly revenue estimates of $43.91 million representing a decline from $47.20 million in Q1 2026, investors will scrutinize whether the company can maintain momentum in surgeon adoption of its bunion correction systems. The year-over-year revenue comparison shows an estimated 7.32% decline from the prior year's Q2 figure of $47.39 million, raising questions about market saturation and competitive pressures.

Path to profitability: Treace has consistently posted losses, and the widening year-over-year loss estimate signals ongoing challenges in achieving breakeven. Analysts will focus on operating leverage, gross margin trends, and management's timeline for reaching sustained profitability as the company scales its commercial operations.

Commercial execution and guidance: Following a pattern of earnings beats over the past four quarters, investors expect management commentary on sales force productivity, procedure volumes, and any updates to full-year guidance. The company's ability to balance growth investments with expense discipline will be critical to maintaining investor confidence.

Analyst commentary ahead of the release reflects cautious optimism tempered by profitability concerns, with the consensus maintaining a Hold-equivalent rating despite recent technical strength in the stock.

Part 2: Historical Earnings Performance

Treace Medical Concepts has established a consistent pattern of beating earnings estimates over the past four quarters, demonstrating better-than-expected operational execution. In Q1 2026, the company reported a loss of $-0.28 per share versus estimates of $-0.31, representing a 9.68% positive surprise. This followed a particularly strong Q4 2025 performance, where the company posted $-0.12 per share against expectations of $-0.15, a 20.00% beat that marked the largest surprise in the recent period.

The trend of outperformance extends across the trailing year, with Q3 2025 delivering a 7.14% beat ($-0.26 actual vs. $-0.28 estimated) and Q2 2025 posting a 3.45% surprise ($-0.28 actual vs. $-0.29 estimated). This consistency suggests management has effectively managed expectations and demonstrated operational discipline, with the company beating estimates in all four of the most recent quarters.

While the magnitude of beats has varied—ranging from 3.45% to 20.00%—the unbroken streak of positive surprises indicates Treace has built credibility with the investment community. However, investors should note that despite these beats, the company remains unprofitable, and the absolute loss levels have fluctuated between $-0.12 and $-0.28 per share over this period, reflecting the ongoing challenge of achieving sustained profitability.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Treace Medical Concepts typically reports earnings before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price action around Treace earnings reveals significant volatility, with an average absolute Day 0 move of 5.27% and Day +1 move of 12.45%. The Day +1 reaction has proven particularly dramatic, more than doubling the initial Day 0 response and suggesting that investors often reassess their initial reactions as they digest management commentary and guidance.

The most extreme post-earnings moves occurred in November 2024 and November 2025, with Day +1 swings of 35.07% and -28.33% respectively, highlighting the stock's capacity for outsized reactions. More recently, the May 2026 report saw a 4.69% Day 0 gain followed by a -3.48% Day 1 reversal, while February 2026 produced an -11.43% Day 0 decline that extended to -10.75% on Day 1.

The average Day 0 trading range of 10.30% and Day +1 range of 16.84% underscore the heightened intraday volatility surrounding these events. Investors should prepare for potential double-digit percentage swings in either direction, with historical patterns suggesting the Day +1 session often determines the ultimate post-earnings trajectory.

Part 2.2: Options Market Expected Move

The options market is currently pricing in a 0.00% expected move for the upcoming earnings release, which stands in stark contrast to the stock's historical average absolute move of 5.27% on Day 0 and 12.45% on Day +1. This absence of implied volatility pricing suggests either extremely thin options liquidity or data unavailability, leaving investors without a clear market-derived expectation for post-earnings movement.

Part 3: What Analysts Are Saying

Analyst sentiment on Treace Medical Concepts reflects mixed conviction, with a consensus rating of 3.00 (Hold) and an average price target of $4.67. The current analyst breakdown shows 1 Strong Buy, 4 Hold, and 1 Strong Sell rating among the 6 analysts covering the stock, indicating a lack of strong directional conviction in either direction.

The average price target of $4.67 implies approximately 6.6% upside from the current price of $4.38, suggesting modest appreciation potential if the company meets expectations. However, the wide range of price targets—from a low of $3.00 to a high of $7.00—reveals significant disagreement among analysts about the company's valuation, with the high estimate implying 59.8% upside while the low estimate suggests 31.5% downside risk.

Analyst sentiment has remained unchanged over the past month, with the 3.00 consensus rating holding steady and no meaningful shift in the distribution of buy, hold, and sell recommendations. The stability in ratings suggests analysts are waiting for clearer evidence of either accelerating growth or meaningful progress toward profitability before adjusting their stances. One analyst moved from Hold to Strong Buy in the past month, but this was offset by another downgrade, leaving the overall sentiment balanced at neutral.

Part 4: Technical Picture

Treace Medical Concepts enters earnings with strong technical momentum, as reflected in the Barchart Technical Opinion showing an 88% Buy signal, up from 80% just one week ago and matching the month-ago reading. This improvement in the near-term signal suggests building positive momentum heading into the release.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates robust near-term momentum with all short-term indicators aligned positively
• Medium-term (100% Buy): Unanimous buy reading confirms the intermediate-term trend remains firmly supportive
• Long-term (50% Buy): Moderate buy signal reflects a more balanced longer-term outlook, suggesting some caution about sustainability

Trend Characteristics: The combination of Average strength and Average direction indicates a steady, moderate uptrend without extreme momentum characteristics—a relatively stable technical environment heading into the volatility of an earnings release.

The stock is trading at $4.38, positioned above its 10-day ($4.34), 20-day ($4.32), 50-day ($4.11), 100-day ($2.99), and 200-day ($3.01) moving averages, though it sits below the 5-day moving average ($4.58). This broad-based support across longer-term moving averages confirms the uptrend, while the slight pullback from the 5-day average suggests recent consolidation.

The stock has demonstrated impressive longer-term momentum, trading 45.8% above its 200-day moving average and 46.5% above its 100-day average, reflecting a sustained recovery from earlier lows. The 50-day moving average at $4.11 provides nearby support, while the recent high near $4.58 (the 5-day moving average) represents immediate resistance. The overall technical setup is supportive heading into earnings, with multiple layers of moving average support below current levels providing a cushion against potential disappointment, though the strong recent run-up also means the stock has less room for error if results or guidance disappoint.